Skip to content
Clinical Trials – home

Futuremeds Łódź

Verified siteinfoFast reply

Poland Ul. Gruszowa 2, 91-363 Lodz, Poland

  • 1 trial recruiting
  • Obesity · Overweight · Sjogren's syndrome
  • Adult patients

About Specializations

Futuremeds Łódź in Lodz, Poland specialises in clinical trials of conditions such as Obesity, Overweight, Sjogren's syndrome, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases and Immune System Phenomena

At Futuremeds Łódź, clinical research focuses on immune-related conditions and the ways the immune system behaves in disease. The main condition under study is Sjögren’s Syndrome With Moderate-toSevere Symptom State, with trials designed to better understand and assess new treatment options for patients living with persistent symptoms.

  • Evaluating a new therapy for Sjögren’s syndrome
  • Studying patient-reported symptoms in moderate-to-severe disease
  • Exploring how treatment may improve immune system-related outcomes

The research at this site is centered on improving care for people affected by autoimmune disease, with attention to symptom relief, treatment effectiveness, and overall patient experience.

Sjögren’s Syndrome Research

This site is also contributing to focused studies on Sjögren’s Syndrome, a chronic immune system disease that can cause significant discomfort and quality-of-life challenges. The trials are intended to evaluate whether a new therapy can help reduce symptoms and support better day-to-day functioning for patients with more severe symptom burden.

  • Assessing symptom improvement in Sjögren’s syndrome
  • Measuring patient-centered treatment benefit
  • Supporting development of better options for autoimmune disorders

With a small but specialized portfolio of studies, Futuremeds Łódź is helping advance research aimed at improving treatment choices for this uncommon but impactful condition.

Patient-Reported Outcomes in Autoimmune Research

The clinical trials at this health care site place strong emphasis on how patients feel and function, not just on disease markers. In particular, the research looks at patient-reported symptoms in Sjögren’s syndrome, helping determine whether investigational treatments may offer meaningful relief for people with moderate-to-severe symptoms.

  • Focusing on symptom burden in chronic immune disease
  • Testing whether treatment can improve daily well-being
  • Advancing care for immune system processes and related disorders

These studies reflect a broader effort to make clinical trial research more relevant to patients by examining real-world symptom change and treatment impact.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Gruszowa 291-363 LodzPoland
Recruiting now
1 trial
Conditions studied
18
Partner status
Verified site

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

16 clinical trials

A study to evaluate the effect of CX11 trometamol monohydrate in patients with type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Vaccines US Inc.

Obesity+1

Not yet recruiting

Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Diabetes mellitus+2

Not yet recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Rheumatoid arthritis

Not yet recruiting

Study on the Effectiveness and Safety of Tocilizumab and Methotrexate for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Dr Reddy's Laboratories Limited

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:PolandPoland
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Study on Insulin Glargine for Patients with Type 2 Diabetes: Comparing Decentralized, Hybrid, and Standard Clinical Trial Approaches

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Universitair Medisch Centrum Utrecht
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.